Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.66 |
| ▸ | CDK2 | P24941 | 2/20 | 0.59 |
| ▸ | IRAK4 | Q9NWZ3 | 10/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.53 |
| ▸ | FLT3 | P36888 | 3/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4804170 | 0.82 | DYRK1A (0.66) | DYRK1ACDK2IRAK4MAPK10PKM | |
| SCHEMBL21194142 | 0.79 | MAP3K14 (0.51) | IRAK4FLT3GABRA1GABRG2GABRB3 | |
| SCHEMBL3557515 | 0.78 | DYRK1A (0.65) | DYRK1ACDK2IRAK4MAPK10PKM | |
| SCHEMBL27637599 | 0.78 | CDK2 (0.78) | DYRK1ACDK2IRAK4PKMMAPK8 | |
| SCHEMBL1684639 | 0.78 | CDK2 (0.67) | DYRK1ACDK2IRAK4PKMMAPK8 | |
| SCHEMBL2197827 | 0.78 | GABRA1 (0.50) | DYRK1ACDK2MAPK8MAPK9FLT3 | |
| SCHEMBL29543829 | 0.77 | CDK2 (0.69) | DYRK1ACDK2IRAK4MAPK10MAPK8 | |
| SCHEMBL28722161 | 0.77 | CDK2 (0.69) | DYRK1ACDK2IRAK4MAPK10MAPK8 | |
| SCHEMBL17943211 | 0.76 | CDK2 (0.77) | DYRK1ACDK2IRAK4MAPK10PKM | |
| SCHEMBL3548686 | 0.76 | DYRK1A (0.62) | DYRK1ACDK2IRAK4MAPK10PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550099-B2 | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-10550099-B2 | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| EP-3194383-B1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS INC (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-3194383-B1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS INC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20190263779-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190263779-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190210995-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20190210995-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-10280150-B2 | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors | FORMA TM2, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-10280150-B2 | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors | FORMA TM2, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| EP-2401274-B1 | IMIDAZO[1,2-A]PYRIDINES AS JNK MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-10-22 | — | — | EP | disclosed |
| US-8569306-B2 | JNK modulators | HOFFMANN-LA ROCHE, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2401274-A1 | IMIDAZO [1, 2 -A]PYRIDINES AS JNK MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| US-20110306618-A1 | JNK Modulators | BUETTELMANN BERND (DE) | 2011-12-15 | — | — | US | disclosed |
| WO-2010097335-A1 | IMIDAZO [1, 2 -A] PYRIDINES AS JNK MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-02 | — | — | WO | disclosed |
| CN-100415744-C | 2-arylamino-pyrimidines for the treatment of GSK3-related disorders | ASTRAZENECA AB (SE) | 2008-09-03 | — | — | CN | disclosed |
| CN-1294131-C | Pyrimidine compound | ASTRAZENECA AB (SE) | 2007-01-10 | — | — | CN | disclosed |
| CN-1823064-A | 2-arylamino-pyrimidines for the treatment of GSK 3-related disorders | ASTRAZENECA AB (SE) | 2006-08-23 | — | — | CN | disclosed |
| CN-1174981-C | Imidazo [1, 2-A ] pyridine and pyrazolo [2, 3-A ] pyridine derivatives | — | 2004-11-10 | — | — | CN | disclosed |
| CN-1537112-A | Pyrimidine compound | — | 2004-10-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280150-B2 | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors | IDH1, IDH3A, IDH3B | DYRK1A 1299/4885CDK2 106/4885IRAK4 4749/4885 |
| US-20190210995-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH2, IDH3A | DYRK1A 2754/4885CDK2 233/4885IRAK4 4481/4885 |
| US-10550099-B2 | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors | IDH1, IDH3A, IDH3B | DYRK1A 1299/4885CDK2 106/4885IRAK4 4749/4885 |
| US-20190263779-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | DYRK1A 1299/4885CDK2 106/4885IRAK4 4749/4885 |
| US-20110306618-A1 | JNK Modulators | MAPK3, MAPK1, MAPK4 | DYRK1A 174/4885CDK2 150/4885IRAK4 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.